CRSP241206C45000
- 6.98
- +1.11+18.91%
CRISPR Therapeutics Newsroom
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95
RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $94
Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Crispr Therapeutics AG: Hold Rating Amid Mixed Financial Performance and Clinical Developments
Crispr Therapeutics Price Target Maintained With a $84.00/Share by Needham
CRISPR Therapeutics Analyst Ratings
Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Crispr Therapeutics AG (CRSP) Gets a Buy From Mizuho Securities
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics Analyst Ratings
RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating
CRISPR Therapeutics Analyst Ratings
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating